Delivery Order SPE2DB22D1106-SPE2DB24FEGR5

Award Date 3/25/24
Potential Completion Date 3/26/24
Potential Value $4.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a delivery order valued at $1,647.10 to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of 4,564,756,209 units of 1% Lidocaine HCl 50 mg/5 ml vials. This order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC allows DLA to efficiently procure essential pharmaceutical products and medical...
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $5,327.64 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 4% lidocaine hydrochloride solution. This contract is a task order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which has a ceiling value of up to $999,999,999.00 through December 2025. The IDC enables DLA to efficiently procure a comprehensive...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on November 1, 2024. The contract is a Delivery Order valued at $1,437.58 for the supply of a 4% Lidocaine HCL solution, with a period of performance through November 4, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical as a primary vehicle for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The $2,234.54 firm fixed price contract is for the supply of Lidocaine HCL 4% Solution 4ML, a medication product. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a...
This is a firm fixed price delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $1,011.32 order is for the supply of Lidocaine HCL 4% Solution 4ML, a pharmaceutical product. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,057 firm fixed-price delivery order is for the supply of 4% Lidocaine HCL solution, a medical product used in various healthcare settings. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award to Amerisourcebergen Drug Corp is a delivery order under the company's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at $999,999,999 through November 2026. The contract covers the delivery of 4,565,294,512 units of 4% lidocaine hydrochloride solution in 4 mL vials, with a ceiling value of $1,516.98 and a completion date of July 31, 2024. This delivery order is not designated as a set-aside contract....
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The delivery order, valued at $1,233.12, is for the supply of 4% Lidocaine Hydrochloride Solution, a medical product used for pain management. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which Amerisourcebergen Drug Corp holds with the DLA Troop Support Medical. This IDC serves as the...
The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a $3,067.84 firm fixed price delivery order contract to provide Lidocaine HCL 2% 200 mg/10 ml, a pharmaceutical product, by February 27, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value up to $999,999,999.00 and a performance period through December 31, 2025. The IDC serves...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $4,191.54 firm fixed price delivery order is for the supply of 4% lidocaine hydrochloride solution (4 ml) to support military healthcare programs. The award is not designated as a set-aside contract. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB24FEGR5
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $4,240.24 to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, to provide 4% lidocaine hydrochloride solution. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA to deliver a comprehensive range of pharmaceutical products and medical supplies in support of military treatment programs and facilities worldwide. The IDC does not have a set-aside designation and was awarded solely to Amerisourcebergen Drug Corp as a single award contract, which serves as the primary vehicle for the company to provide these critical healthcare materials to the Department of Defense.

Generated 6/24/24, 9:20 AM